01 — At a Glance
The Pharma Factory Where Your Paracetamol Gets Made (Eventually)
- 52-Week High / Low₹575 / ₹312
- Q3 FY26 Revenue₹602.9 Cr
- Q3 FY26 PAT₹40.5 Cr
- Q3 FY26 EPS₹4.44
- Annualised EPS (Q3×4)₹17.76
- Book Value₹161
- Price to Book2.13x
- Dividend Yield0.58%
- Debt / Equity0.39x
- CRISIL RatingAA- / Stable
The Setup: Aarti Drugs makes the active ingredients in your medicines — painkillers, antibiotics, diabetes pills, antiprotozoals — you name the therapy, they’re probably synthesizing it. They ship 50+ APIs to 100+ countries. Yet their Q3 EBITDA margin of 9.3% looks like they’re making paint, not pharmaceuticals. Why? Two greenfield projects (Sayakha amines + Salicylic acid) are tanking utilization, supply chain chaos from China is real, and one “voluntary refurbishment” knocked out capacity. But ask management: “It’s temporary. Growth is coming.” Sure, ji. And your 6–month return is -34.7%. Coincidence?
02 — Introduction
The Boring Ingredient Business That Just Isn’t Boring Anymore
Aarti Drugs. Even the name sounds like what would happen if a PowerPoint presentation became a pharmaceutical company. Zero pizzazz. 100% functional. Exactly what the Indian pharma supply chain ordered.
The company manufactures Active Pharmaceutical Ingredients (APIs) — the chemical compounds that actually do the work inside a medicine. While your local pharma company (Cipla, Lupin, Sun Pharma) slaps a fancy name on a tablet and sells it to you for ₹500, Aarti Drugs is supplying the ₹50 worth of actual chemistry hiding inside. Thankless job. Necessary job. Very, very profitable job — until greenfield capacity ramps and everyone in China decides to price-dump.
Established in 1984 as part of the ₹1,000 crore Aarti Group of Industries, the company operates 9 manufacturing facilities (APIs) + 3 more (Specialty Chemicals), collectively holding 61,053 MTPA (Metric Tonnes Per Annum) of installed capacity across Maharashtra and Gujarat. They’re the world’s largest manufacturers of certain molecules like Fluoroquinolones and Tinidazole. Global exports span 100+ countries. CRISIL rates them AA-/Stable — bank-loan-grade credit quality. And yet, watch the stock chart from the past five years: -14.5% return. Ouch.
Q3 FY26 delivered ₹602.9 crore in revenue (+8% YoY), but EBITDA margin collapsed to 9.3% (vs 11.6% in 9M FY26). Management’s explanation? Greenfield drag. One-time shutdown. China supply chaos. Formulations exports were the hero. Let’s dig into what’s actually happening inside this global pill factory.
Concall Reality (Feb 2026): Management explicitly told investors that the margin dip was “temporary.” They expect 12–13% EBITDA to return first, then target 14–15% steady-state. The Sayakha greenfield (methylamines for metformin APIs) was running at 30% utilization in Q3, targeting 50% by Mar/Apr 2026. Translation: pain is not over yet.
03 — Business Model: WTF Do They Even Do?
Making The Invisible Ingredients That Cure Your Grandma
The business is three-part: (1) APIs (81% of revenue), (2) Formulations (11%), and (3) Specialty Chemicals & Intermediates (8%). Think of it as the undercarriage of the pharmaceutical supply chain — unglamorous, essential, and absolutely crucial when it breaks.
APIs: The company manufactures 50+ drug molecules across antibiotics, antifungal, anti-inflammatory, anti-diabetic, antiprotozoal, and anti-malarial categories. They’re global-scale manufacturers — the largest producer of Fluoroquinolones (antibiotic family), Tinidazole (antiprotozoal), Metronidazole Benzoate, Celecoxib (pain), Nimesulide (pain), Ketoconazole (antifungal), and among the top three global producers of Metformin (diabetes). Export markets account for 61% of revenue. Top 10 customers = 22% of revenue; no customer concentration risk.
Formulations: Through wholly-owned subsidiary Pinnacle Life Science (Baddi, Himachal Pradesh), they manufacture 80+ finished dosages. In Q3 FY26, formulations revenue hit ₹76.6 crore (+58% YoY), with exports at 67% of formulation sales — a genuine growth engine. Oncology (FDA-approved manufacturing site) is ramping: first commercialization expected Q4 FY26. This is where the margin upside lives.
Specialty Chemicals: Backward integration. They make benzene sulfonyl chloride, chlorosulphonation derivatives, and now methylamines (Sayakha greenfield). The idea: control cost, secure supply, improve margins. Except when the greenfield eats margin while ramping.
Antibiotic45%Q3 Mix
Antidiabetic16%Growth Driver
Antiprotozoal14%Steady Performer
Formulations+58% YoYExport Star
Therapy Mix Note: Antibiotics dominate (45%), but that’s also their biggest pain point — weak antibiotic demand in Q3 depressed overall utilization. Antidiabetic is growing because Metformin production is scaling post-Sayakha backward integration. Management targets full backward integration of methylamines (currently 10–15% of metformin needs) to 90–100% within 2–3 quarters. When that happens, gross margins lift “at least a couple of percent.”
💬 If you manufacture the active ingredient in your diabetes medication, do you trust the quality more? Are you aware of where your API comes from? Tell us in comments.
04 — Financials Overview
Q3 FY26: The Numbers That Hurt
Result type: Quarterly Results (Q3 FY26) | Q3 EPS: ₹4.44 | Annualised EPS (Q3×4): ₹17.76 | FY26 full year (9M): ₹15.31
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 602.9 | 557 | 653 | +8.1% | -7.7% |
| Operating Profit (EBITDA) | 56.3 | 62 | 84 | -10.2% | -33.0% |
| EBITDA % | 9.3% | 11.1% | 12.9% | -180 bps | -360 bps |
| PAT | 40.5 | 37 | 45 | +9.5% | -10.0% |
| EPS (₹) | 4.44 | 4.06 | 4.96 | +9.4% | -10.5% |
The Real Story Behind The Numbers: Q3 EBITDA margin of 9.3% is a screamer. Here’s why it’s temporarily terrible: (1) Sayakha greenfield running at 30% utilization (targeting 50–75% by Q4), dragging EBITDA by ~₹8–8.5 crore. (2) One-time voluntary shutdown for “European audit refurbishment” — cost about ₹14–15 crore at PBT level. (3) Inventory sales (finished goods from buffer stock) accounted for ~₹30 crore of revenue, reducing gross margin by ~1% (inventory is 80% raw material, 20% overhead, so under-absorption hurt). (4) China supply delays extended lead times, hurting production scheduling. But Q3 also saw formulations exports surge 58% YoY, which supported overall growth. Management’s January sales were “encouraging,” signaling inflection. Wait for Q4 before losing sleep.
05 — Valuation: Fair Value Range
Is Aarti Drugs Cheap, or Just Broken Right Now?
